We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
5.00 | 0.29% | 1,733.50 | 1,732.50 | 1,733.00 | 1,739.50 | 1,724.50 | 1,733.00 | 4,237,056 | 16:35:18 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.48 | 71.35B |
TIDMGSK
RNS Number : 3631K
GlaxoSmithKline PLC
04 May 2022
GlaxoSmithKline plc
Results of 22(nd) Annual General Meeting
GlaxoSmithKline plc ('GSK') held a hybrid Annual General Meeting ('AGM') at 2.30pm on Wednesday 4 May 2022. Shareholders were able to join virtually via Lumi, Zoom and in person at the meeting held at the Sofitel Hotel in Terminal 5 Heathrow.
All valid proxy votes (whether submitted electronically or in hard copy form) were included in the poll taken at the meeting.
The table below shows the results of the poll on all 28 resolutions. The full text of the resolutions is contained in the Notice of AGM published on 28 March 2022, which is available on GSK's website at www.gsk.com .
Resolution Total votes % Total votes % Total votes Votes for (1)(2) against cast withheld (2) (3) Receive and adopt the 2021 Annual 1 Report 3,524,582,633 99.01 35,137,552 0.99 3,559,720,185 11,843,164 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Approve the Annual 2 report on remuneration 3,240,737,115 91.05 318,510,405 8.95 3,559,247,520 12,317,062 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Approve the Remuneration 3 Policy 2,197,755,545 61.76 1,360,515,540 38.24 3,558,271,085 13,294,793 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Election of Dr 4 Anne Beal 3,546,443,179 99.55 16,055,842 0.45 3,562,499,021 9,042,781 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Election of Dr 5 Harry Dietz 3,545,845,271 99.54 16,469,238 0.46 3,562,314,509 9,224,475 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 6 Sir Jonathan Symonds 3,482,374,837 97.76 79,898,313 2.24 3,562,273,150 9,274,730 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 7 Dame Emma Walmsley 3,555,195,651 99.79 7,564,971 0.21 3,562,760,622 8,806,465 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 8 Charles Bancroft 3,503,934,446 98.36 58,393,472 1.64 3,562,327,918 9,214,474 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 9 Vindi Banga 3,483,288,426 97.79 78,881,291 2.21 3,562,169,717 9,373,841 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 10 Dr Hal Barron 3,546,018,185 99.54 16,347,031 0.46 3,562,365,216 9,173,855 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 11 Dr Vivienne Cox 3,531,865,048 99.14 30,474,324 0.86 3,562,339,372 9,204,548 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 12 Lynn Elsenhans 3,476,281,291 97.58 86,142,909 2.42 3,562,424,200 9,118,541 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 13 Dr Laurie Glimcher 3,556,622,114 99.84 5,547,225 0.16 3,562,169,339 9,375,696 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 14 Dr Jesse Goodman 3,555,655,121 99.82 6,515,409 0.18 3,562,170,530 9,367,820 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 15 Iain Mackay 3,551,784,186 99.71 10,432,989 0.29 3,562,217,175 9,333,434 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-election of 16 Urs Rohner 3,410,175,068 95.74 151,806,419 4.26 3,561,981,487 9,561,680 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Re-appointment 17 of the auditor 3,557,280,686 99.84 5,797,033 0.16 3,563,077,719 8,481,780 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Remuneration of 18 the auditor 3,555,233,064 99.86 5,000,395 0.14 3,560,233,459 11,338,880 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Authority for the company to make donations to political organisations and incur political 19 expenditure 3,493,409,287 98.64 48,161,797 1.36 3,541,571,084 30,003,446 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Authority to allot 20 shares 3,430,993,149 96.35 130,127,471 3.65 3,561,120,620 10,593,875 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Disapplication of pre-emption rights - general 21 power (4) 3,460,375,320 97.24 98,220,644 2.76 3,558,595,964 12,963,416 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Disapplication of pre-emption rights - in connection with an acquisition or specified capital 22 investment (4) 3,404,168,390 95.65 154,942,194 4.35 3,559,110,584 12,448,092 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Authority for the company to purchase its own shares 23 (4) 3,517,497,794 98.79 43,085,674 1.21 3,560,583,468 10,990,502 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Exemption from statement of senior statutory auditor's 24 name 3,523,554,816 99.59 14,359,955 0.41 3,537,914,771 33,655,391 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Authority for reduced notice of a general meeting other than 25 an AGM (4) 3,331,432,180 93.62 227,176,994 6.38 3,558,609,174 12,950,914 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Approve the Share 26 Save Plan 2022 3,508,449,940 98.62 49,235,709 1.38 3,557,685,649 13,896,262 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Approve the Share 27 Reward Plan 2022 3,516,666,377 98.86 40,690,090 1.14 3,557,356,467 14,160,284 ------------------------- -------------- ------ -------------- ------ -------------- ----------- Approve the adoption of new Articles of Association 28 (4) 3,549,030,121 99.80 6,964,097 0.20 3,555,994,218 15,501,889 ------------------------- -------------- ------ -------------- ------ -------------- -----------
Resolution 3 - Approval of the Remuneration Policy
The Company was pleased that the new remuneration policy was supported in a vote at today's Annual General Meeting. It also notes that a significant minority were not able to support the new policy at this time. The Company undertook an in-depth consultation process with the majority of its largest shareholders in developing the revised policy and will continue to engage to ensure it fully understands the views of all shareholders on these matters, and to continue to explain the rationale for the changes.
Notes:
(1) The "for" votes include those giving the Chair discretion. In line with the notification issued to American Depositary Receipt (ADR) holders last year, GSK did not instruct its ADR Depositary to vote any unvoted ADRs in respect of the AGM resolutions.
(2) Votes "for" and "against" are expressed as a percentage of the total votes cast.
(3) A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "for" or "against" a resolution.
(4) Indicates Special Resolutions requiring a 75% majority.
The following table provides further information on participation in the AGM:
GSK's GSK's Twenty second Twenty first AGM AGM (Hybrid meeting) (Virtual meeting) (2022) (2021) Issued share capital (excluding Treasury Shares) 5,083,974,547 5,031,444,276 ------------------- -------------------- Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares) 70.25% 70.11% ------------------- -------------------- Total shareholder population 89,764 100,906 ------------------- -------------------- Total number of proxies lodged 5,343 6,089 ------------------- -------------------- Number of shareholders in attendance 93 in person 142 participated 68 participated virtually virtually ------------------- -------------------- % of shareholders who lodged proxies 5.95% 6.03% ------------------- --------------------
The above poll results will shortly be available on the company's website at www.gsk.com . In accordance with Listing Rule 9.6.2, a copy of the resolutions, other than those concerning ordinary business, will be submitted to the UK Listing Authority and will in due course be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism
V A Whyte
Company Secretary
4 May 2022
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGBKQBQABKDAPK
(END) Dow Jones Newswires
May 04, 2022 12:49 ET (16:49 GMT)
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions